WO2015068121A1 - Process for preparation of crystalline form i of linezolid and its compositions - Google Patents
Process for preparation of crystalline form i of linezolid and its compositions Download PDFInfo
- Publication number
- WO2015068121A1 WO2015068121A1 PCT/IB2014/065837 IB2014065837W WO2015068121A1 WO 2015068121 A1 WO2015068121 A1 WO 2015068121A1 IB 2014065837 W IB2014065837 W IB 2014065837W WO 2015068121 A1 WO2015068121 A1 WO 2015068121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- linezolid
- crystalline form
- solution
- solid
- temperature
- Prior art date
Links
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 134
- 229960003907 linezolid Drugs 0.000 title claims abstract description 132
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 27
- 239000007787 solid Substances 0.000 claims abstract description 41
- 239000002904 solvent Substances 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 238000004090 dissolution Methods 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 4
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- 239000007916 tablet composition Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 238000009491 slugging Methods 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 5
- -1 crystalline Chemical compound 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- XKGUZGHMWUIYDR-UHFFFAOYSA-N benzyl n-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical compound C=1C=C(N2CCOCC2)C(F)=CC=1NC(=O)OCC1=CC=CC=C1 XKGUZGHMWUIYDR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
Definitions
- the present invention provides a process for preparing crystalline form I of Linezolid, which comprises:
- a process for the preparation of Linezolid in the crystalline form I comprising providing a solution of linezolid in a solvent, crystallizing and recovering the solid of Linezolid in crystalline form I at an elevated temperature.
- step b) crystallizing from the solution of step a) at an elevated temperature; and c) recovering the solid of step b) at a temperature of above 40 °C to provide crystalline form I of Linezolid.
- step b) crystallizing from the solution of step a) at an elevated temperature; and c) recovering the solid of step b) at a temperature of about 40 °C to provide crystalline form I of Linezolid.
- step b) crystallizing from the solution of step a) at a temperature of above 80 °C; and c) recovering the solid of step b) at a temperature of about 80 to 100°C to provide crystalline form I of Linezolid.
- Linezolid used for providing a solution may be synthesized by a process described in the prior art, for example, US 5,688,792 or the process as described in the following scheme:
- the crystallization may be initiated by the cooling, stirring, partial distillation of the solvent, adding anti-solvent, seeding or combination thereof.
- the crystallization in the present invention is carried out at an elevated temperature, for example, above 40 ° and below 100 °C.
- the solution of the present invention is cooled to 85 °C to about 95 °C and maintained for a period of about 1 to 2 hours or more to enhance the crystallization of Linezolid solid at the same temperature.
- the solid of crystalline form I is recovered from the solution.
- the step of recovering the solid involves filtration by gravity or by suction, centrifugation, decantation, and the like at an elevated temperature of about 40 °C or about 75 °C.
- the solid may optionally be washed with suitable solvent such as water and then subjected for drying at elevated temperature, for example, 75 to 80 °C.
- the drying may be carried out in a vacuum oven, air oven, fluidized bed drier, spin flash dryer, flash dryer and the like for any time period necessary to achieve desired quality of the product, for example, 5 hours or more.
- the resultant crystalline form I of Linezolid of the present invention is characterized by their X-ray powder diffraction ("XRPD") pattern by using Cu Ka radiation, having the wavelength 1.541 A using a Bruker X-ray Diffractometer D8.
- XRPD X-ray powder diffraction
- the crystalline form I of Linezolid is characterized by having X-ray diffraction pattern as shown in Fig. 1 comprising at least 4 characteristic peaks at diffraction angles 2-theta of 7.3, 9.3, 13.5, 14.7, 18.0, 18.4, 18.7, 19.8, 21.0, 22.1, 25.4, 27.6 and 29.6 ⁇ 0.2 degrees.
- the crystalline form I of Linezolid obtained from the present invention is substantially free of residual solvent that is the content of residual solvent is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ("ICH") guidelines, for example, the content of DMF is less than about 500 ppm or less than about 100 ppm or less than 50 ppm.
- a tablet pharmaceutical composition comprising a filler or a diluent, which can be selected from several alternatives well known in the art.
- Suitable diluents or fillers include but are not restricted to lactose, sucrose, glucose, sorbitol, dextrates, dextrins, dextrose, fructose, mannitol, sorbitol, starch, carboxymethylcellulose calcium, microcrystalline cellulose (MCC), powdered cellulose, sodium chloride and mixtures thereof.
- MMC microcrystalline cellulose
- microcrystalline cellulose is the most preferred filler.
- a tablet pharmaceutical composition comprising a binder which can be selected from but not restricted to methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxymethylpropyl cellulose, polyvinylpyrrolidone (povidone), and polyvinylalcohol. Hydroxypropyl cellulose and polyvinylpyrrolidone is the most preferred binder.
- Example 1 Preparations of linezolid form-I.
- Example 3 Preparations of linezolid form-I from linezolid form-II.
- the layers were separated and the aqueous layer was stirred with dichloromethane (2x500ml).
- the total organic layer was collected and combined with water (500 ml) and subjected for pH adjustment of 1.5-2.0 with 15% aqueous HC1 solution (180-200.0ml) at 25-30°C.
- the resultant two layers were separated and then the aqueous layer was stirred with dichloromethane (2x300 ml).
- the aqueous layer was separated, treated with ceca carbon (10 gm) at 25-30 °C, filtered through hyflow bed and then washed the bed with water (200 ml).
- the filtrate was cooled to 20-25 C and then adjusted pH 6.5-6.8 by 25% aqueous NaOH solution (5-7 ml).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3508/MUM/2013 | 2013-11-06 | ||
| IN3508MU2013 IN2013MU03508A (enrdf_load_stackoverflow) | 2013-11-06 | 2014-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015068121A1 true WO2015068121A1 (en) | 2015-05-14 |
Family
ID=52144768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2014/065837 WO2015068121A1 (en) | 2013-11-06 | 2014-11-06 | Process for preparation of crystalline form i of linezolid and its compositions |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2013MU03508A (enrdf_load_stackoverflow) |
| WO (1) | WO2015068121A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105566242A (zh) * | 2016-01-12 | 2016-05-11 | 江苏豪森药业集团有限公司 | 利奈唑胺及其中间体的制备方法 |
| CN110483431A (zh) * | 2019-09-04 | 2019-11-22 | 桂林南药股份有限公司 | 利奈唑胺杂质化合物、其制备方法以及其应用 |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995007271A1 (en) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| WO1999024393A1 (en) | 1997-11-07 | 1999-05-20 | Pharmacia & Upjohn Company | Process to produce oxazolidinones |
| US6559305B1 (en) | 2000-02-02 | 2003-05-06 | Pharmacia & Upjohn Company | Linezolid—crystal form II |
| US20060111350A1 (en) | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
| WO2007026369A1 (en) | 2005-08-29 | 2007-03-08 | Symed Labs Limited | A novel amorphous form of linezolid |
| WO2007064818A1 (en) | 2005-12-01 | 2007-06-07 | Teva Pharmaceutical Industries Ltd. | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
| US7649096B2 (en) | 2005-07-15 | 2010-01-19 | Glenmark Pharmaceuticals Limited | Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide |
| US7714128B2 (en) | 2003-10-16 | 2010-05-11 | Symed Labs Limited | Crystalline form of linezolid |
| WO2011051384A1 (en) | 2009-10-28 | 2011-05-05 | Synthon Bv | Process for making crystalline form a of linezolid |
| WO2011077310A1 (en) | 2009-12-26 | 2011-06-30 | Alembic Limited | Process for the preparation of linezolid |
| US20110275805A1 (en) | 2009-01-13 | 2011-11-10 | Lianhe Chemical Technology Co., Ltd. | Method for preparing linezolid and intermediates thereof |
| WO2012019862A1 (en) | 2010-08-11 | 2012-02-16 | Synthon B.V. | Process for making linezolid |
| WO2012119653A1 (en) | 2011-03-09 | 2012-09-13 | Synthon Bv | Process for making crystalline form a of linezolid |
| CN102850290A (zh) | 2012-10-10 | 2013-01-02 | 天津市炜杰科技有限公司 | 晶型i型利奈唑胺的制备方法 |
| EP2593440A1 (en) | 2011-02-24 | 2013-05-22 | Lee Pharma Limited | Anhydrous linezolid crystalline form-ii |
| WO2013072923A1 (en) | 2011-09-19 | 2013-05-23 | Cadila Healthcare Limited | Process for the preparation of crystalline linezolid |
| WO2013093751A1 (en) | 2011-12-24 | 2013-06-27 | Alembic Pharmaceuticals Limited | Packaging for linezolid |
| WO2013120496A1 (en) | 2012-02-14 | 2013-08-22 | Pharmathen S.A. | Process for the preparation of linezolid in crystalline form and salts thereof |
| WO2014101064A1 (zh) * | 2012-12-27 | 2014-07-03 | 上海创诺医药集团有限公司 | 一种制备利奈唑胺晶型i的方法 |
-
2014
- 2014-11-06 IN IN3508MU2013 patent/IN2013MU03508A/en unknown
- 2014-11-06 WO PCT/IB2014/065837 patent/WO2015068121A1/en active Application Filing
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995007271A1 (en) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| WO1999024393A1 (en) | 1997-11-07 | 1999-05-20 | Pharmacia & Upjohn Company | Process to produce oxazolidinones |
| US6559305B1 (en) | 2000-02-02 | 2003-05-06 | Pharmacia & Upjohn Company | Linezolid—crystal form II |
| US7714128B2 (en) | 2003-10-16 | 2010-05-11 | Symed Labs Limited | Crystalline form of linezolid |
| US20060111350A1 (en) | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
| US7649096B2 (en) | 2005-07-15 | 2010-01-19 | Glenmark Pharmaceuticals Limited | Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide |
| WO2007026369A1 (en) | 2005-08-29 | 2007-03-08 | Symed Labs Limited | A novel amorphous form of linezolid |
| WO2007064818A1 (en) | 2005-12-01 | 2007-06-07 | Teva Pharmaceutical Industries Ltd. | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
| US20110275805A1 (en) | 2009-01-13 | 2011-11-10 | Lianhe Chemical Technology Co., Ltd. | Method for preparing linezolid and intermediates thereof |
| WO2011050826A1 (en) | 2009-10-28 | 2011-05-05 | Synthon B.V. | Process for making crystalline form a of linezolid |
| WO2011050865A1 (en) | 2009-10-28 | 2011-05-05 | Synthon B.V. | Process for making crystalline form a of linezolid |
| WO2011051384A1 (en) | 2009-10-28 | 2011-05-05 | Synthon Bv | Process for making crystalline form a of linezolid |
| WO2011077310A1 (en) | 2009-12-26 | 2011-06-30 | Alembic Limited | Process for the preparation of linezolid |
| WO2012019862A1 (en) | 2010-08-11 | 2012-02-16 | Synthon B.V. | Process for making linezolid |
| EP2593440A1 (en) | 2011-02-24 | 2013-05-22 | Lee Pharma Limited | Anhydrous linezolid crystalline form-ii |
| WO2012119653A1 (en) | 2011-03-09 | 2012-09-13 | Synthon Bv | Process for making crystalline form a of linezolid |
| WO2013072923A1 (en) | 2011-09-19 | 2013-05-23 | Cadila Healthcare Limited | Process for the preparation of crystalline linezolid |
| WO2013093751A1 (en) | 2011-12-24 | 2013-06-27 | Alembic Pharmaceuticals Limited | Packaging for linezolid |
| WO2013120496A1 (en) | 2012-02-14 | 2013-08-22 | Pharmathen S.A. | Process for the preparation of linezolid in crystalline form and salts thereof |
| CN102850290A (zh) | 2012-10-10 | 2013-01-02 | 天津市炜杰科技有限公司 | 晶型i型利奈唑胺的制备方法 |
| WO2014101064A1 (zh) * | 2012-12-27 | 2014-07-03 | 上海创诺医药集团有限公司 | 一种制备利奈唑胺晶型i的方法 |
Non-Patent Citations (3)
| Title |
|---|
| J. MED. CHEM., vol. 39, no. 3, 1996, pages 673 |
| J. MED. CHEM., vol. 39, no. 3, 1996, pages 673 - 679 |
| TETRAHEDRON LETT., vol. 40, no. 26, pages 4855,1999 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105566242A (zh) * | 2016-01-12 | 2016-05-11 | 江苏豪森药业集团有限公司 | 利奈唑胺及其中间体的制备方法 |
| CN110483431A (zh) * | 2019-09-04 | 2019-11-22 | 桂林南药股份有限公司 | 利奈唑胺杂质化合物、其制备方法以及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IN2013MU03508A (enrdf_load_stackoverflow) | 2015-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113993853B (zh) | 氯苯唑酸及其盐的固态形式 | |
| KR20080064908A (ko) | 카르베딜올 | |
| WO2012090043A1 (en) | Novel solid state forms of azilsartan medoxomil and preparation thereof | |
| CN101939287A (zh) | (1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的结晶变体 | |
| WO2016005874A1 (en) | Process for the preparation of regorafenib and its crystalline forms | |
| WO2021154980A1 (en) | Solid state forms of asciminib and processes for the preparation thereof | |
| EP4482836A1 (en) | Solid state forms of gusacitinib | |
| WO2015011659A1 (en) | Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib | |
| WO2015068121A1 (en) | Process for preparation of crystalline form i of linezolid and its compositions | |
| US9403811B2 (en) | Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof | |
| WO2022060758A1 (en) | Solid state forms of sep-363856 and process for preparation thereof | |
| US20250250239A1 (en) | Solid state forms of mavacamten and process for preparation thereof | |
| US20240352014A1 (en) | Solid state forms of vericiguat and process for preparation thereof | |
| WO2020168144A1 (en) | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt | |
| US20060293377A1 (en) | Amorphous and polymorphic forms of telmisartan sodium | |
| JP2024541422A (ja) | タファミジスの固体状態の形態 | |
| WO2022040111A2 (en) | Solid state forms of erdafitinib salts and processes for preparation of erdafitinib | |
| US20060270684A1 (en) | Crystalline forms of ziprasidone mesylate | |
| WO2020198429A1 (en) | Solid state forms of acalabrutinib | |
| US20240294479A1 (en) | Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid | |
| CN111320596A (zh) | 盐酸美呋哌瑞多晶型物及其制备方法 | |
| US12404267B2 (en) | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt | |
| WO2025141467A1 (en) | Solid state forms of lorundrostat and process thereof | |
| WO2025094081A2 (en) | Solid state forms of deutivacaftor and process thereof | |
| US20220220149A1 (en) | Solid state forms of sage-217 and processes for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14816396 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14816396 Country of ref document: EP Kind code of ref document: A1 |